This Article Full Text Full Text (PDF) All Versions of this Article: 1/3/153    most recent CIRCEP.108.769471v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sacher, F. Articles by Stevenson, W. G. Search for Related Content PubMed PubMed Citation Articles by Sacher, F. Articles by Stevenson, W. G. Related Collections Arrhythmias, clinical electrophysiology, drugs Ablation/ICD/surgery Related Articles

Original Articles

Ventricular Tachycardia Ablation

Evolution of Patients and Procedures Over 8 Years

Frédéric Sacher, MD; Usha B. Tedrow, MD; Michael E. Field, MD; Jean-Marc Raymond, MD; Bruce A. Koplan, MD; Laurence M. Epstein, MD and William G. Stevenson, MD

From Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to William G. Stevenson, Cardiac Arrhythmia Department, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115. E-mail frederic.sacher{at}chu-bordeaux.fr

Received January 28, 2008; accepted May 1, 2008.

Background— Evolving management of coronary artery disease, heart failure, and the use of implantable cardioverter-defibrillators impacts the characteristics of patients with recurrent ventricular tachycardia (VT). We investigated the substrate, procedure, and outcome evolution of all patients referred for VT ablation during the past 8 years.

Methods and Results— From 1999 to 2006, 493 consecutive patients (358 male, 57±16 years) underwent 623 VT ablations: 131 had no structural heart disease (SHD), 213 had ischemic cardiomyopathies (ICMP), and 149 had nonischemic cardiomyopathies (NICMP). Although the main substrate is ICMP, the proportion of NICMP has increased from 27% to 35% (P=0.06) from 1999–2002 to the 2003–2006. The procedure abolished or modified inducible VTs in 75% of patients in all groups, but abolition of all monomorphic VTs was achieved in 125 (83%) patients without SHD, 180 (65%) with ICMP, and 99 (51%) with NICMP (P<0.0001). During a mean follow-up of 3.3±2.4 years, no deaths occurred in patients without SHD, but 75 patients (35%) with ICMP and 26 patients (17%) with NICMP died after a median of 13 months. Multivariate Cox regression analysis found that age, ejection fraction, and need for preprocedural mechanical hemodynamic support predicted mortality.

Conclusions— The substrate causing VT in patients requiring ablation is evolving and determines the long-term outcome. In the setting of a normal heart, VT ablation is associated with a low risk of subsequent mortality, with no deaths occurring during a mean follow-up of >3 years. In contrast, in patients with SHD and recurrent VT, VT ablation can be helpful to suppress drug refractory VT, but long-term mortality remains significant.

Key Words: tachycardia • catheter ablation • mortality • ventricles

---

 

CLINICAL PERSPECTIVE

Guest Editor for this article was Douglas P. Zipes, MD.

Related Articles

Ventricular Tachycardia Ablation: Moving Beyond Treatment of Last Resort

Francis E. Marchlinski
Circ Arrhythm Electrophysiol 2008 1: 147-149. [Extract] [Full Text] [PDF]

Ventricular Tachycardia Ablation: Evolution of Patients and Procedures Over 8 Years

Frédéric Sacher, Usha B. Tedrow, Michael E. Field, Jean-Marc Raymond, Bruce A. Koplan, Laurence M. Epstein, and William G. Stevenson
Circ Arrhythm Electrophysiol 2008 1: 153-161. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				F. E. Marchlinski Ventricular Tachycardia Ablation: Moving Beyond Treatment of Last Resort Circ Arrhythm Electrophysiol, August 1, 2008; 1(3): 147 - 149. [Full Text] [PDF]